Race to stop ebola: new Two-Drug shield tested for those just exposed
NCT ID NCT06841614
Summary
This trial aims to find the best way to prevent Ebola in people who have just had a high-risk exposure, like contact with a sick person's body fluids. It will compare giving a vaccine alone versus giving the vaccine plus an antibody treatment. The goal is to stop the exposed person from developing the full, deadly disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guinea Centre for Research and Training in Infectious Diseases (CERFIG)
Conakry, Guinea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Institute for Biomedical Research (INRB)
Kinshasa, Democratic Republic of the Congo
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Public Health Institute of Liberia
Monrovia, Liberia
Contact Email: •••••@•••••
-
University of Sierra Leone College of Medicine and Allied Health Sciences
Freetown, Sierra Leone
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.